Trial Profile
OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE IB STUDY WITH EXPANSION PHASE TO EVALUATE THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF RO5509554 AND MPDL3280A ADMINISTERED IN COMBINATION IN PATIENTS WITH ADVANCED SOLID TUMORS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Aug 2020
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Emactuzumab (Primary)
- Indications Advanced breast cancer; Bladder cancer; Gastric cancer; Ovarian cancer; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions
- Sponsors Roche
- 26 Aug 2020 Status changed from active, no longer recruiting to completed.
- 10 Jul 2020 Planned End Date changed from 29 May 2020 to 17 Jul 2020.
- 10 Jul 2020 Planned primary completion date changed from 29 May 2020 to 17 Jul 2020.